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Abstract
Background
Objective: To determine to what extent each trial met criteria specified in three research
frameworks for ethical trial conduct.
Design: Systematic review and narrative analysis
Methods and findings
Data sources: MEDBASE and EMBASE databases were searched using a specific search
strategy. The Cochrane database for systematic reviews, the PROSPERO database and
trial registries were examined. A grey literature search and citation search were also carried
out.
Eligibility criteria for selecting studies: Studies were included where the intervention
was being used to treat Ebola in human subjects regardless of study design, comparator or
outcome measured. Studies were eligible if they had taken place after the 21st March 2014.
Unpublished as well as published studies were included.
Included studies: Sixteen studies were included in the data synthesis. Data was
extracted on study characteristics as well as any information relating to ten ethical areas of
interest specified in the three research frameworks for ethical trial conduct and an additional
criterion of whether the study received ethics approval from a research ethics committee.
Synthesis of results: Eight studies were judged to fully comply with all eleven criteria.
The other eight studies all had at least one criteria where there was not enough information
available to draw any conclusions. In two studies there were ethical concerns regarding the
information provided in relation to at least one ethical criteria.
Description of the effect: One study did not receive ethical approval as the authors
argued that treating approximately one hundred patients consecutively for compassionate
reasons did not constitute a clinical trial. Furthermore, after the patients were treated, physi-
cians in Sierra Leone did not release reports of treatment results and so study conclusions
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had to be made based on unpublished observations. In another study the risk-benefit ratio
of the trial drug does not appear to be favourable and the pre-trial evidence base for its effec-
tiveness against Ebola is speculative.
Conclusions
Some limited and appropriate deviation from standard research expectations in disaster sit-
uations is increasingly accepted. However, this is not an excuse for poor ethics oversight
and international regulations are in place which should not be ignored. New guidelines are
needed that better define the boundaries between using medicines for compassionate use
and conducting a clinical trial. Greater support should be offered for local research ethics
committees in affected areas so that they can provide robust ethical review. Further system-
atic reviews should be carried out in epidemics of any novel infectious diseases to assess if
comparable findings arise.
Introduction
Background
The 2014 Ebola outbreak is the most widespread epidemic of the highly lethal viral haemorrha-
gic disease with 11,310 confirmed deaths as of the 10th June 2016 [1]. It resulted in a rapid
increase in research into potential Ebola treatments and vaccines [2,3]. However, as of Novem-
ber 2016, there is no licensed drug therapy against Ebola and currently recovery is dependent
on a combination of best supportive care and the patient’s immune response [4].
It is argued that deviation from standard research expectations to an appropriate extent in a
disaster setting may be acceptable [5–7]. In the case of Ebola, in August 2014, the World
Health Organisation (WHO) concluded that it would be acceptable to use unregistered treat-
ments that had shown promising results in animal models but had not been tested for safety or
efficacy in humans [8]. Importantly, this was conditional on certain criteria being met, includ-
ing a number of ethical requirements. These include but are not limited to: transparency about
care, fairness, informed consent, freedom of choice, confidentiality, respect for the person, pre-
serving dignity, risk-benefit assessment and community involvement [8].
Why is this review important?. According to the most recent WHO report on research
and development of Ebola therapies, there are fifteen Ebola treatment trials currently in prog-
ress [9]. Questions have been raised about whether two of these were carried out in an ethically
appropriate manner, relative to exceptional circumstances of the Ebola crisis:
1. Fedson et al. prescribed approximately 100 consecutive patients atorvastatin and irbesartan
under compassionate use to treat Ebola [10]. The authors stated a 2% mortality rate was
achieved, compared to a mean mortality of 40% in the current outbreak [1]. However, there
was no formal documentation of the patients’ treatment and these mortality rates appear to
be given verbally as an unpublished observation by one of the study authors [10].
2. One study was registered on the Pan African Clinical Trials Registry Committee but was
later withdrawn [11]. It proposed assessing the efficacy and safety of amiodarone in Ebola
patients despite pre-clinical data on antiviral activity of amiodarone being extremely limited
[12]. Previously, amiodarone had been given as a compassionate therapy to 65 patients with
Ebola, of whom 63% died. The authors acknowledge that there was no evidence to suggest
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that amiodarone had any beneficial effect on these patients [12]. Therefore, some clinicians
have asked whether, given amiodarone’s potentially toxic side-effects, it is ethically accept-
able to give amiodarone off-licence to treat Ebola [13].
A systematic review of all Ebola treatment trials to determine the extent to which studies
have complied with international and local ethical standards for research is therefore timely. If
trials have not conformed to ethical norms, then this may suggest a greater need for transpar-
ency and accountability from researchers in any future situation where a novel infectious dis-
ease precipitates a medical emergency; such as a new strain of influenza.
Objectives
The aim of this systematic review is to examine all Ebola treatment trials that were conducted
during the 2014 outbreak and systematically review whether they satisfied international
research ethics requirements. Three published ethical frameworks were used to derive a set of
criteria against which to compare studies. These were those published by the WHO, Me´decins
Sans Frontières (MSF) and a framework by Emanuel, Wendler and Grady which has been
designed specifically for use in developing countries [14–16].
These frameworks were initially chosen as they are peer-reviewed, internationally recog-
nised frameworks. In a recent literature review, the Research for Health in Humanitarian Cri-
ses described all three ethical frameworks as milestones in addressing ethical concerns in
disaster settings [17]. Secondly, the frameworks were developed by organisations from differ-
ing backgrounds- a specialised agency within the United Nations (WHO), a global non-gov-
ernmental organisation (MSF) and a research team from the National Institutes of Health
(Emanuel et al.). Therefore, the frameworks contain subtle differences accommodating the
wide range of opinions about the essential ethical components for ethical trial conduct. These
differences will be compared in more detail later in this review.
The objectives of this systematic review are:
Primary Objective. To determine the extent to which each trial meet criteria specified in
the three research frameworks for ethical trial conduct.
Secondary Objective. To compare the three ethical frameworks and to suggest how they
can be modified and improved in light of the systematic review.
Methods
Protocol and registration
The systematic review protocol was ineligible for registration on the PROSPERO database
because it is concerned solely with the ethics of clinical trials and, as such, has no directly
health-related outcomes. The protocol for this systematic review is reported in S3 Appendix.
Eligibility criteria
Study characteristics. Study design: The review included all study designs. Studies were
eligible for inclusion even if the trial had been withdrawn as this reflects the ethical implica-
tions of starting a trial and not completing it.
Populations: Human subjects of any age who are suspected to have Ebola.
Interventions: Any intervention to treat Ebola. Vaccine studies were excluded as this would
broaden the scope of the review too much given the time constraints of the author’s degree
program.
Comparators: All comparators were eligible for inclusion.
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Outcomes: Trials were included regardless of what outcomes they reported as these need to
be assessed to see whether they are ethically acceptable.
Timing: Studies were eligible if they took place after the Ebola outbreak was first identified
on the 21st March 2014 [18].
Setting: No restrictions on the location of trials.
Report characteristics. Language: Non-English studies were eligible for inclusion.
Publication status: Unpublished as well as published articles were identified as unpublished
trials may have been less likely to satisfy ethical criteria.
Information sources
The MEDLINE database (OVID interface, 1946 onwards) and the EMBASE database (OVID
interface, 1974 onwards) were both searched to account for variability in indexing between
databases [19,20]. The Cochrane database was then searched for any systematic reviews from
which any relevant articles were identified [21]. The PROSPERO database of systematic review
protocols was also searched for relevant protocols [22]. The electronic database search was
complemented by searching for trials on the International Clinical Trials Registry Platform,
clinicaltrials.gov and The Pan African Clinical Trials Registry [23–25]. Unpublished studies
were identified through a grey literature search on the System for Information on Grey Litera-
ture in Europe database [26]. To conclude, a citation search of included papers was carried out
to ensure literature saturation.
Search strategy
Medical Subject Headings (MeSH) and terms relating to Ebola therapies since 2014 were used
to create a search strategy. This was developed by the Principal Investigator with advice from
supervisors and a librarian experienced in developing search strategies. The search strategy for
MEDLINE can be found in S4 Appendix. EMBASE uses Emtree subject headings whereas
MEDLINE uses MeSH headings and so the MEDLINE search strategy cannot be transferred
over to Embase without alteration [27]. Therefore, a similar strategy was used for EMBASE
but modified for differences in subject headings between the databases. These modifications
should not have implications on the articles chosen for inclusion in this review [27]. The strat-
egies were peer reviewed by a fellow intercalating student who advised to either broaden or
reduce their comprehensiveness as necessary. After the literature search on MEDLINE and
EMBASE, the other information sources listed in the previous section were examined using
‘Ebola’ as the sole search term. These other information sources contained a relatively small
number of records which were all be assessed for inclusion and so there was no need to create
a narrower search strategy as in MEDLINE and EMBASE search strategies.
Study selection
Data management. All literature search results were loaded onto a Microsoft Excel
spreadsheet. Two researchers independently assessed the results for duplicate studies by com-
paring author names on studies as well as abstracts of studies. If studies appeared to be dupli-
cates, they were read in full to determine if they were identical reports one of which could then
be excluded.
Selection process. To screen for inclusion, the title and abstract of each study was assessed
independently by two researchers against eligibility criteria. Full text copies of articles were
then accessed and a check for eligibility was repeated. Any disagreements were noted and were
discussed with a supervisor who decided if a paper should be included. Reasons for exclusion
Extent to Which Ebola Treatment Trials Adhere to Ethical Guidelines
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were recorded and a record was kept of the extent of agreement at each stage of the selection
process.
Data collection process
Data extraction was carried out by a single researcher with independent verification provided
by a supervisor who checked the extraction forms for accuracy. The data extraction forms can
be found in S5 Appendix. Where required information appeared to be unreported, the trial
authors were contacted via email for up to three attempts.
Data items
Data was extracted from eligible studies and uploaded onto an excel spreadsheet. Data com-
prised specific study characteristics; most importantly, on the extent to which the study design
and preliminaries reflected the ethical criteria laid out in the three research ethics frameworks.
These included whether the trial was approved by a research ethics committee and ten areas
which amalgamated criteria contained in the three frameworks. These criteria are summarised
in Table 1.
Risk of bias in individual studies
As the majority of studies have not yet been published, it was decided that no formal assessment
for risk of bias would be carried out. Instead, information on study conduct was extracted and
Table 1. Simplified table of the ten sections that make up the three ethical frameworks. Sections are coloured BLUE if a similar section is present in all
three frameworks, GREEN if they appear in two frameworks and YELLOW if they are only in one framework.
Criteria
Number
WHO Emanuel et al. MSF
1 Scientific design and conduct of the study Scientific validity • What is the research question?
• Why is it important?
• How is the methodology and proposed analysis
appropriate given the research question(s)?
2 Risks and potential benefits Favourable risk-benefit
ratio
• What are the anticipated harms and benefits?
3 Protection of research participants’ privacy
and confidentiality
Respect for participants • How do you plan to protect confidentiality?
• How do you plan to access, store and distribute any
collected biological material?
• What will happen when the research is either stopped
or is complete?
• How will the findings be disseminated?
• How will the findings be implemented?
4 Informed consent process Informed consent • What are your plans for obtaining consent?
5 Community considerations Collaborative partnership,
social value
• What is the context in which the research will be
conducted?
• How has this influenced the research design?
• Are there any other parties involved in the research?
• What potential interests of these parties might conflict
with MSF’s mission and values?
6 Selection of study population and
recruitment of research participants
Fair participant selection
7 Inducements, financial benefits and
financial costs
8 Independent review
9 Are all relevant resources for the research secured?
10 Have the research staff the relevant training and
protection?
doi:10.1371/journal.pone.0168975.t001
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presented as part of the results. The discussion will outline whether each choice of study design
was appropriate given the exceptional circumstances of the Ebola outbreak.
Summary measures
A systematic narrative analysis was carried out to analyse the extent to which studies met ethi-
cal criteria. Any answers missing data or data of concern will be described in the results and
elaborated on in the discussion.
Risk of bias across studies
We did not measure for the cumulative quality of the studies as this is not relevant to our
review.
Results
Study selection
We identified 952 records by systematically searching MEDLINE (n = 417), EMBASE
(n = 383), Cochrane Database of Systematic Reviews (n = 2), the PROSPERO Database of Sys-
tematic Review Protocols (n = 11) and three trial registries (n = 139). After removing duplicate
articles, a total of 522 non-duplicate records were identified. Records were then screened by
title and then abstract. Due to the specific study and report characteristics stated in the eligibil-
ity criteria, we were able to exclude 493 articles at this point. The full texts of 29 articles were
then read and, of these, 13 were excluded. Reasons for exclusion at each stage are stated in the
PRISMA Flow Diagram (see Fig 1).
Initially, the two researchers had an 84% degree of agreement in the selection of eligible
articles. After meeting, degree of agreement increased to 88%. Following a subsequent meeting
Fig 1. PRISMA Flow Diagram.
doi:10.1371/journal.pone.0168975.g001
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with a supervisor, the extent of agreement reached 100%. In total, 16 studies were included in
the data extraction and synthesis [28–43]. 13 studies were identified through the trials registry
search alone whilst the remaining three were published on MEDLINE and EMBASE databases.
Contact details were available for 15 studies [28–32,34–43]. Authors were emailed up to three
times with a request for missing information. Replies were received for 11 of the studies (69%)
[28–30,35–39,41–43].
Study characteristics
Tables 2, 3 and 4 list the characteristics of the population, intervention, comparator and pri-
mary outcome of each study as well as details on setting, sample size, study design, trial status
and publication status. The total number intended number of participants in the studies is
approximately 1800 patients although actual enrolment is likely to be less as many trials were
initiated as the incidence of Ebola was decreasing. As of the 27th October 2016, only four of the
trials had published results [28,29,39,41]. Eight studies have been completed [28,29,32–34,36–
38], one is still recruiting [40], three others are enrolling by invitation only [35,42], one has
been withdrawn [30], and one is not yet recruiting patients [31].
Comparison of ethical frameworks. Table 1 shows the key areas of the ethical frame-
works designed by the WHO, MSF and by Emanuel et al. respectively [14–16]. Five of the ten
distinct ethical areas that this review identified appeared in all three frameworks. These can be
summarised under the headings: scientific design, conduct and validity of the study, risks and
potential benefits, protection of research participants’ privacy and confidentiality, process for
gaining informed consent and community considerations. One area, ‘selection of study popu-
lation and recruitment of research participants’, was included by the WHO and Emanuel but
not MSF. The four remaining areas were included in only one of the three frameworks. The
section on ‘inducements, financial benefits and costs’ was taken from the WHO framework,
‘independent review’ was specified in Emanuel’s paper whilst ‘resources for the research and
protection’ and ‘training of research staff’ were contained within the MSF ethical guidelines.
Results of individual studies
Data on each study was extracted on the following eleven criteria which indicate the extent to
which studies adhered to ethical guidelines. These ethical criteria include the ten criteria which
amalgamate the three research ethics frameworks mentioned previously as well as whether the
trial was approved by a research ethics committee. This additional criterion is important as
approval by a research ethics committee suggests that a study protocol has, in the opinion of
the committee, adhered to research ethics guidelines which are based in part on the criteria
stated in research ethics frameworks.
The data extraction sheets for each study can be found in the appendix (see S5 Appendix).
Trials may not require all eleven elements to be considered as adhering to ethical guidelines.
Indeed, the ethical frameworks from which these ethical criteria were drawn differ in terms of
criteria prioritised and these differences will be described later. A detailed outline of the ethical
frameworks by the WHO, MSF and Emanuel et al. can be found in S6 Appendix.
Ethical protocol. In total, fourteen trials were confirmed to have favourable ethical review
through either viewing their ethical approval certificate or a declaration on the trials registry
stating ethical approval had been granted {28–32,34,35,37–43]. In one trial, we could not con-
firm whether ethical approval had been granted and authors did not respond when contacted
[33]. The authors of another study reasoned that giving approximately 100 consecutive pa-
tients atorvastatin and irbesartan constituted compassionate use and did not require ethical
approval [36].
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Appropriate scientific design, conduct and validity. Four studies used randomisation as
part of their study design [30–33]. Twelve trials stated that randomisation would not occur
[28,29,34–43]. Of the former, one study used an adaptive study design [31]. One study had no
study design as such; but treated approximately one hundred patients consecutively. Upon
completion of this study, physicians in Sierra Leone did not release reports of the treatment
results and the study authors state that ‘it will be up to others to rigorously review and validate
these findings’ [36]. One study is a Phase 1 clinical trial [35], four are listed as Phase 1/2
[31,32,34,43], five are Phase 2 clinical trials [29,33,39,41,42] and three were listed as Phase 2/3
trials [28,30,38]. Three studies did not state which phase they were in [36,37,40].
Favourable risk-benefit ratio. Fifteen studies specified that the intervention being tested
would have a favourable balance of potential risks and benefits due to the high mortality rate
for those who contract Ebola [28–39,41–43]. However, physicians have questioned the risk-
benefit balance of a trial using amiodarone [13]. They argue that the adverse effects of amio-
darone are not offset by the antiviral activity of the intervention as pre-clinical data on this is
extremely limited. Moreover, mortality rates did not significantly decrease when the interven-
tion was used previously to treat Ebola [13,30]. For one trial there was insufficient information
available to assess the potential risks and benefits [40].
Protection of research participants’ privacy and confidentiality. Eight of the studies
stated that identifiable information was protected and only accessible to research staff
[28,29,35,38,39,41–43]. One trial stated that patients’ blood samples would be destroyed fol-
lowing testing but arrangements for other patient identifiable data were not included [37].
Insufficient information was available to warrant any definitive statements in seven of the
studies [30–34,36,40].
Appropriate informed consent process. Fourteen trials stated that written informed con-
sent was required to participate and specified procedures for those who did not have capacity
to consent [29–35,38–43]. One trial did not reference informed consent in their inclusion cri-
teria and authors did not respond to our requests for further information [37]. Fedson et al.
did not gain informed consent from study participants [36]. This was justified on the grounds
that physicians would be acting in the best interests of patients when administering the inter-
vention under compassionate use and; therefore, consent was not necessary.
Collaborative partnership between researchers and community. In eight studies, the
authors specified measures to communicate trial information to the local community [28,29,
35,38,39,41–43]. In addition, two trials offered psychological and social support to those par-
ticipating [39,41]. In one trial, Caucasian researchers were not used to inject the intervention
to mitigate local fears that westerners were injecting people with Ebola [43]. Another trial
ensured that consultations were held with patients and their families at four pre-defined points
during the trial [29]. We were not provided with sufficient information to make any definitive
judgments in eight of the studies [30–34,36,37,40].
Fair participant recruitment and selection. Sixteen studies stated inclusion criteria of
participants with polymerase chain reaction (PCR) confirmed Ebola virus [28–43]. One of
these studies also included those who were strongly suspected of having Ebola that had not
been confirmed by PCR testing [42]. Nine studies allowed pregnant women to participate but
excluded children aged two years old or younger [28,31,32,35,36,38,40,42,43]. One study
excluded pregnant women but did not exclude children [41]. Five studies excluded older chil-
dren: three excluded those under 18 years old [34,40,43], one patients under 13 years [33] and
one excluded those under 9 years old [37].
Inducements, financial benefits and costs. In nine studies, intervention and all treat-
ment, regardless of trial arm, was provided without cost to participants [28,29,35,36,38,39,41–
43]. Two trials provided participants with mobile phones to enable follow up [39,41]. In two
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trials, reasonable travel expenses and compensation were offered [35,42]. Another trial stated
expenses were only available to plasma donors but not those receiving the intervention [38]. In
one study, social aid was provided to help patients return home or to assist with the family’s
burial if a patient died [29]. In two other studies, no compensation was provided to partici-
pants [28,43]. In another study, a private donation enabled the medication to be delivered to
Sierra Leone [36]. We were not provided with enough information on this area to warrant any
definitive statements in seven studies [30–34,37,40].
Independent review. The involvement of both Research Ethics Review Boards and Data
and Safety Monitoring Boards were considered when assessing independent review. One
study did not undergo independent review as there was no written study protocol to be
reviewed [36]. Three of the trials sought independent review from the WHO [39,41–43]. Two
trials were reviewed by the U.S Food and Drug Administration and the Wellcome Trust
respectively [35,38]. Three trials stated that an independent Data and Safety Monitoring Board
was appointed to ensure continuous monitoring of their respective studies [28,29,38]. We
were not provided with sufficient information to make statements in seven studies [30–
34,37,40].
Resources for the research. Fourteen studies gave an institution as their primary spon-
sor; responsible for the management, financing and legal liabilities of the trial [28–35,37–
42]. One trial gave an individual as their sponsor [43]. Seven trials specified an additional
organisation also responsible for the funding of the trial [31,34,38,39,41–43]. One study did
not have financial support from any organisations [36]. Instead, one of the authors made a
private donation to bring the intervention (irbesartan and atorvastatin) into Sierra Leone
[36].
Protection and training of research staff. Four studies were conducted in hospitals run
by MSF where staff members are required to meet specified standards of training [28,29,39,41].
In two other trials, staff received specialist training to provide convalescent plasma to patients
[35,38]. One trial ensured all researchers received training on infection prevention and con-
trol [42]. In another trial, twelve Guineans were trained to international standards for con-
ducting clinical trials [43]. One study did not provide additional training for research staff
[36]. We were not provided with sufficient information to make statements in seven studies
[30–34,37,40].
Discussion
Summary of evidence
In total, eight studies appeared to fully comply with all eleven ethical criteria [28,29,35,38,39,
41–43]. The other eight studies had at least one criteria where there was not enough informa-
tion available to draw any conclusions [30–34,36,37,40]. In four studies there was ambiguity
regarding the information provided for at least one ethical area [33,36,37,40]. In two studies
there were ethical concerns regarding the information provided in relation to at least one ethi-
cal criteria [30,36]. Table 5 categorises each study’s ethical trial performance in the ten ethical
areas into a traffic light system to help illustrate to what extent each trial complies with the eth-
ical criteria.
The rest of this discussion will assess whether the ethical concerns stated above were appro-
priate given the exceptional circumstances of the Ebola outbreak.
According to the 2013 Declaration of Helsinki and similar guidelines, trials that are under-
taking research on human participants are required to submit a trial protocol to research ethics
committee(s) for review and approval [44,45,46]. For two studies, we were unable to find evi-
dence of ethical review:
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1. Zhong et al., did not state on their clinicaltrials.gov page that their trial had been reviewed
by an ethics committee [33]. No contact details were provided and we were unable to find
these independently via an internet search. We could not, therefore, contact the researchers
for clarification.
2. Fedson et al. argued that ethical review was not required as they were not conducting
research as patients were given atorvastatin and irbesartan under compassionate use [36].
Providing drugs to treat patients on compassionate grounds, as is the case for Fedson et al,
has occurred throughout the Ebola epidemic [47,48]. The WHO argued that this was accept-
able provided the clinical data was collected and shared [49]. However, the guidelines for
trialling an intervention under compassionate use are still less vigorous than a clinical trial
requiring ethical approval [50,51]. Therefore, it is important to determine what differentiates
compassionate use from research. WHO define compassionate use as the ‘use of an interven-
tion outside of a clinical trial’ [49]. Furthermore, the WHO reasoned that ‘compassionate use’
may be an inaccurate term in circumstances when an untested intervention is given and data
on its efficacy is systematically collected from individual use. In light of this, in October 2014,
the WHO Ethics Working Group suggested that the term ‘compassionate use’ should be
replaced by the phase ‘monitored emergency use of unregistered and experimental interven-
tions (MEURI)’ in an attempt to better define the often blurred boundary between clinical tri-
als and compassionate use [49].
The WHO definition of compassionate use presents the problem of what defines a clinical
trial. A widely accepted definition by the International Committee of Medical Journal Editors
states that a clinical trial is ‘any research study that prospectively assigns human participants
or groups of humans to one or more health-related interventions to evaluate the effects on
health outcomes’ [52]. Defining research, the US Department of Health defines it as ‘a system-
atic investigation. . .designed to develop or contribute to generalisable knowledge’ [53]. In the
study by Fedson et al there was a systematic process to provide over one hundred consecutive
patients a novel treatment regime (irbesartan and atorvastatin) and systematically collect data
on subsequent mortality rates [36]. Given this information and the aforementioned defini-
tions, it could be argued that the limits for what constitutes ‘compassionate use’, and therefore
does not require prior ethical approval, have been strained.
The use of randomisation in clinical trials has been contentious in the current Ebola out-
break [54–59]. Both randomised and non-randomised study designs were used by the re-
viewed studies. The WHO guidance suggests that all study designs, whether randomised or
not, should be considered provided standards for human research ethics are adhered to [49].
An argument against randomisation is that it may not be acceptable to the local community
who, against the background of Ebola’s high mortality rate, may not understand why some
people are being given a potentially promising treatment whilst others are not [54,55]. On
the other hand, randomising minimises allocation bias and reduces confounding factors
[56,57,58]. Arguably, in the context of this Ebola outbreak, any reasonable and robust study
design, sensitive to local conditions and meeting other ethical standards might be regarded as
acceptable [49,59]. Given that results published so far are from non-randomised trials, there is
insufficient evidence to draw any firm conclusions about the relative merits of each study
design.
The majority of studies demonstrated a clearly favourable balance of potential risks and
benefits given the high fatality rate of Ebola. Concerns have been expressed about the balances
of risks and benefits in the proposed trial by Strada et al. using amiodarone [30]. It was con-
tended that amiodarone is a potentially toxic drug with side-effects including thyroid toxicity
and abnormal ECG changes in hypokalaemic patients [13]. Such risks, it was argued, would
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not be outweighed by the benefits of amiodarone as pre-clinical data on the antiviral activity of
amiodarone is very limited. Moreover, of the 65 patients who were previously given amiodar-
one under compassionate use, 63% died compared to around 50% who were receiving best
supportive therapy at the Ebola treatment unit where the trial took place [13]. This trial did
secure ethical approval from the Sierra Leone research ethics committee who presumably
formed a contrary view about the potential balance of risks and benefits [30]. The importance
of local review, even at times of crisis, cannot be overstated: more support may be needed to
bolster local research ethics review services in disaster settings to provide robust, timely scien-
tific and ethical review.
There were inconsistencies across trials regarding their exclusion criteria for both pregnant
women and children. On the one hand, children should not be excluded from a trial purely on
the basis that they may have diminished autonomy as the informed consent process can be
adapted to accommodate this and appropriate measures taken to ensure confidentiality is
respected [60]. On the other hand, studies may have excluded children on the basis that the
intervention may have adverse outcomes on a child’s growth and development [61]. The usual
norm of requiring that interventions are trialled on adults before children may not protect the
interests of children in such extreme circumstances where the entire affected population might
be regarded as vulnerable [46]. Similarly, regarding the exclusion of pregnant women, some
studies may have included pregnant women on the basis that the potential benefit to the
mother may outweigh potential teratogenic effects of the intervention on her unborn foetus
[62]. Moreover, the death of a pregnant woman inevitable affects, if no seals, the survival pros-
pects of the foetus. Given that trials registries do not collect information on the reasons behind
exclusion criteria, conclusions about some researchers excluded pregnant women or children
are difficult to make.
Five studies’ originators did not reply to requests for further information. In these cases,
data on the ethical criteria was limited to information in the public domain. This was predomi-
nantly on trials registries where there is no requirement to report information relating to the
following five ethical criteria:
1. Protection of research participants’ privacy and confidentiality
2. Collaborative partnership between researchers and community
3. Inducements, financial benefits and costs
4. Independent review
5. Protection and training of research staff
This is surprising given the importance of these five criteria in promoting ethical conduct.
For instance, Emanuel et al. state that independent review of research protocols enables greater
accountability and reduces concerns surrounding authors’ potential conflicts of interests [16].
Similarly, WHO guidance states that communicating and engaging with local communities is
of paramount ethical importance [14]. Going forward, it would be useful if there were obliga-
tory sections in all trial registries on how these ethical criteria would be met and these sections
should be added to the WHO Trial Registration Data Set [63].
Comparison of ethical frameworks. The 2014–2015 Ebola outbreak was unprecedented
in its magnitude and placed huge strains on fragile healthcare systems in the affected commu-
nities [64]. This, coupled with the absence of any specific treatment for Ebola owing to the rela-
tive lack of research carried out in previous outbreaks, contributed to the exceptional
circumstances of this disaster [65]. In this respect, it is important to acknowledge that some
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ethical concerns may need to be prioritised over others for clinical trials to take place in such
circumstances.
The three research ethics frameworks are well established yet each specifies at least one ethi-
cal area that is missing from the other two frameworks as depicted in Table 1. There are five
criteria which are not present in all three frameworks. The authors of these frameworks pres-
ent logical arguments for why these criteria are essential to fully assess the ethical conduct of a
trial. Therefore, as a minimum standard for research ethical conduct in emergency disaster set-
tings, this review suggests that all trials should conform to the ten ethical areas as summarised
below.
These ten criteria are:
1. Appropriate scientific design, conduct and validity
2. Favourable risk-benefit ratio
3. Protection of research participants’ privacy and confidentiality
4. Appropriate informed consent process
5. Collaborative partnership between researchers and community
6. Fair participant recruitment and selection
7. Inducements, financial benefits and costs
8. Independent review
9. Resources for the research
10. Protection and training of research staff
Limitations
Authors were contacted if data was unreported and given the opportunity to provide this
information. Five authors did not reply to three attempts to contact them. Information regard-
ing the ethical conduct of these trials is, therefore, limited to material in the public domain.
We did not have the resources to assess whether data from pre-clinical, phase one or phase
two studies was available for studies in later phases. Similarly, the amount of data provided by
the authors in correspondence varied greatly and this meant it was not always possible to assess
the extent to which ethical guidelines were met. Twelve studies have not yet published results
and so assessment of ethical conduct was carried out based on information on trial registries,
contact with study authors or, if available, protocols submitted to ethics committees. There-
fore, no conclusions can be made on the extent to which research protocols were adhered to.
Conclusions
The majority of trials adhered to ethical guidelines during this particularly challenging epi-
demic. Although some deviation from standard research norms in disaster situations is widely
accepted, international regulations are in place and should not be ignored [44,46]. The recom-
mendations from this review are threefold:
Firstly, new guidelines should be generated to better define the boundaries between using
medicines for compassionate use and conducting a clinical trial. This should be coupled with
increased standardisation of data sets across clinical trial registries. These changes will pro-
mote greater transparency and accountability when conducting research.
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Secondly, there should be greater support for local research ethics committees to provide
robust, timely, scientific and ethical review in those countries affected by disasters such as
Ebola.
Lastly, we propose a framework for the minimum standards for research ethics in disaster
settings. The framework contains ten criteria, five of which integrate the common criteria con-
tained within the three frameworks assessed in this review. As this was a secondary objective
of the systematic review, a future review of all ethical guidance may highlight other areas of
commonly used criteria as well as differences that can be explored to ensure a consensus on
what a comprehensive, universally applicable guidance should contain.
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